Spero Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases where there is high unmet medical and patient need. Co.'s product candidate, tebipenem pivoxil hydrobromide, is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. Co.'s pipeline also includes SPR720, an oral treatment for non-tuberculous mycobacterial infection. The SPRO stock yearly return is shown above.
The yearly return on the SPRO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SPRO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|